Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicentre, double blind, randomised, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sezary Syndrome (SS) that have achieved disease control with systemic therapy – the RESMAIN Study

Next Previous
Trial Profile

A multicentre, double blind, randomised, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sezary Syndrome (SS) that have achieved disease control with systemic therapy – the RESMAIN Study

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Resminostat (Primary)
  • Indications Cutaneous T-cell lymphoma; Mycosis fungoides; Sezary syndrome; Skin cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms RESMAIN
  • Sponsors 4SC; 4SC AG

    • Most Recent Events

    • 27 Sep 2023 According to a 4SC media release, company received Orphan Drug Designation US Food and Drug Administration (FDA) for resminostat (Kinselby) in cutaneous T cell lymphoma.
    • 25 Sep 2023 According to a 4SC media release, the company is on track to file for European Marketing Approval of Kinselby in Q1 2024.
    • 25 Sep 2023 According to a 4SC media release, the Company will host a live webinar to discuss the findings presented at EORTC.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top